Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

  1. Balar, A.V.
  2. Galsky, M.D.
  3. Rosenberg, J.E.
  4. Powles, T.
  5. Petrylak, D.P.
  6. Bellmunt, J.
  7. Loriot, Y.
  8. Necchi, A.
  9. Hoffman-Censits, J.
  10. Perez-Gracia, J.L.
  11. Dawson, N.A.
  12. van der Heijden, M.S.
  13. Dreicer, R.
  14. Srinivas, S.
  15. Retz, M.M.
  16. Joseph, R.W.
  17. Drakaki, A.
  18. Vaishampayan, U.N.
  19. Sridhar, S.S.
  20. Quinn, D.I.
  21. Durán, I.
  22. Shaffer, D.R.
  23. Eigl, B.J.
  24. Grivas, P.D.
  25. Yu, E.Y.
  26. Li, S.
  27. Kadel, E.E.
  28. Boyd, Z.
  29. Bourgon, R.
  30. Hegde, P.S.
  31. Mariathasan, S.
  32. Thåström, A.
  33. Abidoye, O.O.
  34. Fine, G.D.
  35. Bajorin, D.F.
  36. Montrer des auteurs +
Revue:
The Lancet

ISSN: 1474-547X 0140-6736

Année de publication: 2017

Volumen: 389

Número: 10064

Pages: 67-76

Type: Article

DOI: 10.1016/S0140-6736(16)32455-2 GOOGLE SCHOLAR

Objectifs de Développement Durable